All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Health Canada approve obinutuzumab plus bendamustine for R/R FL patients
On 7th February 2017, Health Canada approved the combination of GAZYVA® (obinutuzumab) and bendamustine followed by GAZYVA® monotherapy for FL patients who relapsed or are refractory to treatment regimens containing rituximab.1
This approval was based on results of the GADOLIN study, a pivotal phase III trial which aimed to compare the efficacy of obinutuzumab plus bendamustine followed by obinutuzumab maintenance (G-B) against bendamustine (B) alone in patients with rituximab-refractory iNHL. The Lymphoma Hub reported updated results of the GADOLIN study, which were presented at ASH 2016. The study included 99 Canadian patients from 10 centers across the country. In the FL patient population, after a median follow-up of 31.2 months, mPFS was significantly higher in G-B arm patients (n = 164) than B arm patients (n = 171); 25.3 vs 14.0 months, respectively (HR, 0.52; 95% CI, 0.39–0.69; P < 0.0001).
The Canadian Cancer Society predict that each year in Canada, approximately 2,800 people are diagnosed with FL.2
Currently, obinutuzumab plus bendamustine followed by obinutuzumab maintenance is approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for rituximab-refractory FL patients. Obinutuzumab is also EMA and FDA approved in combination with chlorambucil to treat patients with treatment naïve CLL.
References